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Parkinson’s disease (PD) is slowly progressive, and heterogeneity of its severity among
individuals may be due to endogenous mechanisms that counterbalance the striatal
dopamine loss. In this perspective paper, we introduce a neuroimaging-genetic approach
to identify genetic variants, which may contribute to this compensation. First, we briefly
review current known potential compensatory mechanisms for premotor and early disease
PD, located in the striatum and other brain regions. Then, we claim that a mismatch
between mild symptomatic disease, manifested by low motor score on the Unified PD
Rating Scale (UPDRS), and extensive Nigro-Striatal (NS) degeneration, manifested by
reduced uptake of [123I]FP-CIT, is indicative of compensatory processes. If genetic variants
are associated with the severity of motor symptoms, while the level of striatal terminals
degeneration measured by ligand uptake is taken into account and controlled in the
analysis, then these variants may be involved in functional compensatory mechanisms
for striatal dopamine deficit. To demonstrate feasibility of this approach, we performed
a small “proof of concept” study (candidate gene design) in a sample of 28 Jewish PD
patients, and preliminary results are presented.
Keywords: Parkinson’s disease, compensatory mechanisms, FP-CIT SPECT, tyrosine hydroxylase, neuroimaging
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INTRODUCTION
Parkinson’s disease (PD) is characterized by progressive degener-
ation of dopaminergic neurons in the substantia nigra, causing
depletion in striatal dopamine level, variable clinical expres-
sions, and a slowly deteriorating course (Dauer and Przedborski,
2003; Obeso et al., 2010). In general, there is an association
between disease severity and disease duration, but the rate
of disease progression is variable among patients. Thus far,
there are no biological markers that can predict rate of dis-
ease progression in an individual patient (Kuriakose and Stoessl,
2010).
The inter-individual difference in severity of motor symp-
toms during early and mid duration of PD may be attributed
to existence or lack of compensatory mechanisms for dopamine
loss (Obeso et al., 2004). Thus far, research of compen-
satory mechanisms has mostly concentrated on the transition
between pre-motor stage and the emergence of the motor symp-
toms (Bezard et al., 2003). However, it is also plausible that
compensatory mechanisms play a role in the motor symp-
tomatic period, thus manipulating disease severity and pro-
gression (Brotchie and Fitzer-Attas, 2009). These functional
mechanisms may counterbalance dopamine loss in early PD,
attenuating the severity and progression of motor symptoms
(Biju and de la Fuente-Fernández, 2009). Identification of such
mechanisms is of major scientific and clinical importance.
Herein we introduce an original approach to discover genetic
variants contribution to endogenous compensatory mechanisms
in early PD, achieved by combining clinical, genetic and neu-
roimaging data. Our hypothesis is that a mismatch between mild
symptomatic disease, manifested by low motor score on the
Unified PD Rating Scale (UPDRS), and extensive Nigro-Striatal
(NS) degeneration, manifested by reduced uptake of [123I]FP-
CIT, is indicative of compensatory processes. Genetic variations
probably predispose some individuals to better compensatory
potential for the striatal dopamine loss. We believe that this type
of systematic research will offer initial tools required to iden-
tify these variants, and to trace genes that may be involved in
compensatory mechanisms.
This perspective paper briefly reviews several of the currently
known compensatory mechanisms in PD. Then, we present our
algorithm and report initial findings of a small “proof of concept”
study for identification of genetic compensatory mechanisms in
early PD. Naturally, the small sample size used in this report is
underpowered, but the goal in this context is to present the new
method and its possible applicability, and not to reach definitive
conclusions.
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COMPENSATORY MECHANISMS IN PRESYMPTOMATIC
AND EARLY PD DISEASE
It is well established that parkinsonian signs appear when 70–80%
of the dopaminergic neurons are already lost (Bernheimer et al.,
1973; Lee et al., 2000; Perez et al., 2008; de la Fuente-Fernández
et al., 2011). The postmortem analysis of parkinsonian brains
indicates that extensive loss of dopamine in the putamen and in
the caudate nucleus can still be accompanied by only minor clin-
ical symptoms (Bernheimer et al., 1973; Agid, 1991). According
to Braak’s pathological staging of PD, the process begins in the
dorsal nucleus of the vagus and the olfactory bulb, reaching
the substantia nigra only in the third pathological stage (Braak
et al., 2003). This explains the appearance of autonomic and
other non-motor symptoms before the appearance of the motor
ones. Another explanation might be that intra- and extrastriatal
compensatory mechanisms are responsible for the late mani-
festation of motor symptoms (Brotchie and Fitzer-Attas, 2009).
After the appearance of the first motor manifestations, degenera-
tion of dopaminergic neurons continues, causing further decline
in motor performance. However, the variability of disease pro-
gression among patients is high, indicating that compensatory
mechanisms play a role also in this stage. These mechanisms may
be related to genetic predisposition, but also to environmental
ones [e.g., consumption of nicotine and caffeine—which have
a neuroprotective effect (Sugita et al., 2001; Quik et al., 2007;
Prediger, 2010)]. Demographic factors, like age at disease onset,
also influence compensatory potential, in favor of younger age
(de la Fuente-Fernández et al., 2011).
STRIATAL COMPENSATORY MECHANISMS THAT AIM TO MAXIMIZE
THE EFFECT OF THE REMAINING DOPAMINE IN THE STRIATUM, PRE-
AND POSTSYNAPTICLLY
Upregulation of enzymes involved in dopamine metabolism
Several studies have shown upregulation of tyrosine hydroxylase
(TH) and aromatic acid decarboxylase (AADC) in brains of ani-
mal models of PD (Zigmond et al., 1984, 1990; Lee et al., 2000),
leading to increased dopamine synthesis in the residual neurons.
Longitudinal PET studies demonstrated that upregulation of
the dopamine synthesis declines as PD progresses (Nandhagopal
et al., 2011). Intranigral injections of 6-hydroxydopamine acceler-
ated the rates of dopamine synthesis and release by the surviving
nigrostriatal neurons by increasing TH activity (Melamed et al.,
1982). Evidence of increased ratio of dopamine metabolites to
dopamine supports this theory (Hefti et al., 1985; Elsworth et al.,
2000; Bezard et al., 2001b). However, it has been shown that
the remaining dopaminergic neurons in the substantia nigra in
patients with PD exhibit lower rather than higher TH mRNA
expression, rendering this theory less plausible (Javoy-Agid et al.,
1990).
Upregulation of D2 dopamine receptor expression on striatal
neurons
Development of striatal dopamine receptor super-sensitivity may
augment responsiveness to remaining dopamine. This phenom-
ena is mainly related to raised level of dopamine D2 receptors.
Several human and primate studies have demonstrated post-
synaptic supersensitivity, mediated by increase of D2 receptors
binding (Creese et al., 1977; Lee et al., 1978; Falardeau et al.,
1988; Todd et al., 1996; Bezard et al., 2001b). This means that
depletion of dopaminergic nigrostriatal output leads to increased
D2 receptors number (onmedium spiny neurons), to compensate
the underactivation of the downstream transduction pathways.
In contrast to D2 receptors, most studies do not support
super-sensitization of D1 receptors following dopamine deple-
tion, in terms of increased number and affinity (Shinotoh et al.,
1993; Hurley et al., 2001; Stoessl et al., 2011), albeit reports of
increased D1 receptors recruitment to the plasma membrane
of medium spiny neurons (Guigoni et al., 2007). Principally,
Increased dopamine receptor expression in the striatum may
attenuate the functional imbalance in PD, characterized by over-
activation of the indirect pathway (see below), and underacti-
vation of the direct pathway (Jenner, 2008). Overexpression of
D2 receptors enhances the inhibitory effect of the remaining
dopamine in the striatum on the activity of the indirect path-
way, while overexpression of D1 receptors might facilitate the
activation of the direct pathway—and delay manifestations of PD
motor symptoms.
Interestingly, alternations of cerebral blood volume in the
striatum are induced by activation or blockade of various
dopamine receptor subtypes (Choi et al., 2006; Sánchez-Pernaute
et al., 2007; Chen et al., 2012). Changes in vascular tone may
occur due to activation of receptors expressed on astrocytes,
affecting basal ganglia response to various stimuli and have a
compensatory role.
Down-regulation of the dopamine transporter (DAT)
In PD, down-regulation of DAT which modulates concentration
of synaptic dopamine should cause decreased dopamine reuptake.
This results in higher concentration of dopamine in the synapse
(Lee et al., 2000; Sossi et al., 2007). Existence of this potential
mechanism is supported by findings of reduced DAT level per
surviving dopaminergic neuron in PD (Uhl et al., 1994).
Structural mechanisms
Other putative compensatory mechanisms are structural, involv-
ing increase in the number of intrinsic striatal TH interneurons.
This neuron population, positioned within the striatum itself,
is able to produce dopamine (Porritt et al., 2000; Huot et al.,
2007). It is still unclear whether these TH neurons growth is a
production of new neurons (neurogenesis), or represents striatal
mature neurons which adopt the TH phenotype and the ability to
produce dopamine (phenotypic shift), acting as a compensatory
mechanism (Tandé et al., 2006; Huot et al., 2007). This pro-
cess might be influenced by several factors, such as presence and
concentrations of required growth factors (e.g., BDNF, GDNF)
(Du and Iacovitti, 1995). In addition, growth factors may sup-
port generation of dopaminergic terminal on the surviving NS
neurons, as well as promote other compensatory structural mech-
anisms within the striatum (Rosenblad et al., 1998; Weinreb et al.,
2007).
Transaxonal regulation
In a recent study, ablation of the TH gene inmice revealed that TH
protein levels in the axon terminals are regulated differently from
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that in the soma, and that tissue dopamine levels are under trans-
axonal compensatory regulation: The reduction of dopamine
in some axons induces enhanced dopamine synthesis in others
(Tokuoka et al., 2011). Trans-axonal compensation may be medi-
ated by phsophorylation of TH, decreased dopamine reuptake or
by neurotrophic factors.
EXTRA STRIATAL COMPENSATORY MECHANISMS
The indirect pathway projects from the striatum to the Globus
Pallidus externa (GPe), and inhibits it via GABAergic transmis-
sion. Reduction of GPe inhibition by the indirect pathway can
serve as a compensatory mechanism to dopamine depletion, and
reduce PD symptoms severity (Brotchie and Fitzer-Attas, 2009;
Black et al., 2010).
Several mechanisms were suggested to reduce activity of the
indirect pathway, in addition to dopaminergic ones. Decreased
glutamatergic excitation probably has a compensatory potential,
andmight bemediated by the endocannabinoid system. Increased
endocannabinoid levels (achieved by lower degradation through
the FAAH enzyme) reduces striatal glutamate release (Gubellini
et al., 2002; Pisani et al., 2005; van der Stelt et al., 2005), and there-
fore attenuate the indirect pathway activity. Other mechanisms
focus on enkephalinergic signaling, which may reduce GABA
release by the terminals of the indirect pathway, and decrease its
inhibitory influence on the GPe (Asselin et al., 1994; Herrero et al.,
1995). There is evidence for upregulation of enkephalin transmis-
sion in PD before the manifestation of motor symptoms (Dacko
and Schneider, 1991; Bezard et al., 2001c), rendering it an attrac-
tive potential compensatory mechanism, balancing the overactive
inhibitory GABA input to GPe.
In animal models, overactivity of the subthalamic nucleus
(STN) and globus pallidum interna (GPi) before the appear-
ance of overt PD symptoms has been demonstrated (Vila et al.,
2000; Obeso and Schapira, 2009). However, it is not clear if these
changes are indeed compensatory by their character.
Deep brain stimulation (DBS) to extra-striatal brain regions
(e.g., Subthalamic nucleus, STN) is an established therapy for
advanced PD, inhibits neuronal activity at stimulation site.
Interestingly, several studies suggested that STN DBS may also
facilitate induction of compensatory mechanisms and networks,
relevant to movement control (Johnson et al., 2008).
CORTICAL AND CEREBELLAR LEVEL
This category of compensatory mechanisms is located in brain
regions and networks involved in motor system control, outside
the basal ganglia (Bezard et al., 2001a; Palmer et al., 2009; Appel-
Cresswell et al., 2010). These regions might adapt themselves to
dopamine depletion state in the straitum, balancing the impaired
basal ganglia function (Palmer et al., 2009). Increased activity
of the Supplementary Motor Area (SMA) and the right dorsal
pre-motor cortex was observed in healthy individual carrying the
PINK1 mutation (interpreted as compensatory to the latent NS
dysfunction) (van Nuenen et al., 2009). There is some support in
animal models that in addition to NS degeneration, a decreased
metabolic activity of the SMA is required to the appearance of PD
motor symptoms (Rascol et al., 1992, 1998). Therefore, increased
SMA activity may delay overt manifestation of motor symptoms.
At the mechanistic level, reduction of regional metabolism in
PD is consistently reported in several cortical areas (Stoessl et al.,
2011). Alternation of cerebral blood flow and volume, as well as
in glucose metabolism may be relevant to compensatory strate-
gies (Appel-Cresswell et al., 2010). In addition, compensatory
and beneficial changes include increased activation of neuronal
networks and recruitment of novels ones (Palmer et al., 2009),
as well as alternation of connectivity patterns between brain
regions (Palmer et al., 2010). For example, compensatory role
for altered dorsal pre-motor cortex activity among PD patients
was found in a visual region in the occipito-temporal cortex (van
Nuenen et al., 2012), as well for increased motor cortical plastic-
ity and reorganization of the sensorimotor cortex (Kojovic et al.,
2012).
Moreover, increased activity of the cerebellum and its pro-
jections may compensate for basal ganglia impaired function
(Cerasa et al., 2006). In a neuroimaging study of motor task
performance, higher activity of the cerebellum compensated for
reduced putaminal activity (Yu et al., 2007). Cortico-cerebellar
circuits are assumed to play a compensatory role, but findings
should be interpreted with caution, since these changes may also
be related to PD pathology itself (Martinu and Monchi, 2012).
A NEW APPROACH FOR IDENTIFICATION OF GENETIC
COMPENSATORY MECHANISMS
Our hypothesis focuses on the possible influence of genetic vari-
ants on severity of symptoms in early PD. We became aware to
patients withmarked decrease of [123I]FP-CIT uptake in the stria-
tum at early stage of the disease, while their clinical phenotype
was compatible with a mild disease. We assume that a mismatch
between dopamine binding and symptom severity may be indica-
tive of compensatorymechanisms that act in the early motor stage
of the disease.
The basic hypothesis for our model is that if genetic vari-
ants are associated with the severity of motor symptoms, while
the level of striatal terminals degeneration measured by striatal
[123I]FP-CIT uptake is taken into account and controlled in the
analysis, then these variants may be involved in functional com-
pensatory mechanisms for the dopamine deficit in the striatum.
Our algorithm is based on a statistical analysis which combines
three parameters: clinical, genetic and neuroimaging data.
Following selection of Single Nucleotide Polymorphisms
(SNPs) of interest and genotyping them in a suitable sample of PD
patients, multivariate linear regression model is implemented to
predict UPDRS score as a function of selected SNPs together with
relevant covariates (gender, age, disease duration). The UPDRS
score (indicator of motor severity evaluated in unmedicated
patients or if already treated with dopaminergic agents, after a
“wash-out” period) is the dependent variable in this association
study, and the SNP genotype is the independent variable (lin-
ear regression). We first force enter [123I]FP-CIT uptake values
as a covariate that controls for degree of striatal terminals degen-
eration. Then, a second block is entered into the model using
stepwise method, contains a single SNP. Thus, this SNP potential
unique contribution to the UPDRS variance could be examined.
This step is performed separately for each of the studied SNPs of
interests.
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To demonstrate the feasibility of this algorithm, we have per-
formed a small “proof of concept” candidate gene study. The
study group consisted of 28 Israeli Jewish patients with early
idiopathic PD who had not yet been treated with any anti-PD
drugs. The study was approved by the Ethics Committee of Rabin
Medical Center, and all patients signed an informed consent
form. All patients underwent [123I]-FP-CIT SPECT within few
weeks from assessment of severity of the motor symptoms by the
UPDRS motor sub-score. For SPECT imaging and analysis, see
Appendix Methods.
Tagging SNPs were selected in 4 candidate genes participating
in dopamine metabolism pathway: tyrosine hydroxylase (TH),
catechol-O-methyltransferase (COMT), and monoamine oxidase
(MAO) A and B. The selection was performed on the basis of
the international HapMap project CEU group data, using the tag-
ger option of the Haploview program, version 4.1 (Barrett et al.,
2005). Criteria for inclusion were minor allele frequency of >5%
and minimum r2 threshold of 0.8. In total, twenty-six SNPs were
successfully genotyped.
The first stage was to evaluate univariate associations between
these SNPs and the UPDRS score. Table A1 shows that only the
rs6356 SNP in the TH gene (encoding for amino acid Val to
Met substitution at position 81) showed a nominal significant
association with the UPDRS score (p = 0.007).
Table 1 shows the clinical characteristics and FP-CIT uptake
data of the whole sample and of the carriers/non-carriers of
the rs6356minor allele. Twenty patients were carriers of the
rs6356 AA/AG genotypes, and 8 were carriers of the major allele
“G” homozygous genotype (GG). There was a trend for shorter
disease duration among the carriers of the “A” allele compared
to homozygotes for the “G” allele (p = 0.06). The mean UPDRS
score was significantly lower in the AA/AG genotype carriers than
the GG homozygotes (p = 0.007) despite the lack of significant
differences in [123]FP-CIT uptake in the contralateral (to themore
affected side of the body) putamen, caudate, or mean putaminal
uptake between these groups (Figure A1).
The second stage examined the effect of rs6356 on disease
severity using stepwise linear regression. The SPECT data and dis-
ease duration (block 1, control variables) were force-entered first,
and then the gene variant was added using the stepwise method
(block 2). The two control variables, by themselves, explained
31% of the inter-individual variance in the UPDRS scores (R2 =
0.31, p = 0.009) (Table 2). After the second block (containing
only the rs6356 SNP) was entered, the model yielded a total
R2 of 0.45. This means that when the duration of PD and the
level of ligand uptake were held constant, the contribution of the
rs6356 “A” allele (AA and AG genotypes) was statistically signif-
icant (p = 0.01), with rs6356 explaining about one-third (R2 =
0.14) of the total variance in UPDRS scores. Adding the genetic
variable to a model that included non-genetic predictors of PD
severity may increase the percentage of variance explained by the
model (Table 2). Similar and consistent results were achieved with
values of the contralateral caudate and mean putamen uptake
(Table A2).
In this example, the Val81Met polymorphism (rs6356) in
the TH gene influences disease severity in our small sample
of patients with early PD. The contribution of this genetic
variant to the prediction of UPDRS score is adjunctive to the
Table 1 | Demographic, clinical, radiotracer uptake values, and descriptive statistics of the whole sample and of carriers and non-carriers of the
rs6365 SNP.





No. of patients 28 20 8
Age (years), mean ± SD 65.7± 7.6 65.6± 7.4 65.8± 8.8 0.94
Males, n (%) 20 (71%) 15 (75%) 5 (62.5%) 0.41*
Disease duration at SPECT (years), mean ± SD 1.73± 1.6 1.4± 1.3 2.6± 0 0.06
UPDRS at SPECT, mean ± SD 9.85± 5.17 8.25± 3.22 13.8± 7.0 0.007
Radiotracer absorption
Contralateral putamen 1.42± 0.6 1.39± 0.53 1.5± 0.77 0.66
Contralateral caudate 2.66± 0.81 2.62± 0.76 2.76± 0.98 0.69
Mean putamen (ipsi- and contralateral) 1.62± 0.65 1.57± 0.58 1.73± 0.84 0.44
*Chi-square test. All other variables were analyzed by t-test. Bold value indicates p < 0.05.
Table 2 | Summary of the linear regression model predicting UPDRS score by model; Block 2 was entered in a stepwise manner.
Block Variable B SE β t p-value Cumulative R2
LINEAR REGRESSION MODEL PREDICTING UPDRS BY TRACER UPTAKE IN THE CONTRALATERAL PUTAMEN
Constant 15.04 3.36 4.47 <0.001
1 Duration of PD (months) 0.937 0.563 0.291 1.664 0.937
Absorption level in contralateral putamen −2.4 1.42 −0.27 −1.69 0.1 0.31 (p = 0.009)
2 rs6356 (carriership of A allele) −4.72 1.86 −0.42 −2.53 0.01 0.45 (p = 0.002)
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combined effect of variables of FP-CIT uptake and disease dura-
tion, as demonstrated by linear regression analysis. In other
words, the genetic variant has an effect onmotor symptoms sever-
ity in PDwhen level of NS degeneration level and disease duration
are held constant, and therefore may be involved in compensatory
mechanisms of the disease.
The results of this “proof of concept” study should be inter-
preted with caution, and may actually represent false-positive
findings, due to the small sample size and the burden of multiple
testing. TH association does not withstand correction for multi-
ple testing (required p-value of 0.002, according to Benofferoni
correction). In general, the best strategy to confirm results of
genetic association studies and to differentiate true positive from
false negative results, is to perform a replication study in an
independent sample. Unfortunately, we do not have access to
a validation sample, which contains the required data for this
analysis. It should be recognized that our sample is unique, as
all participants were of Jewish ancestry (reduced genetic hetero-
geneity), and naïve to anti-Parkinson medications at the time of
clinical assessment and SPECT scanning. If drug-treated patients
are included in future samples, then motor assessment should be
performed following an acceptable “wash-out” period.
Nevertheless, our goal here was to present the novel method
in a “hypothesis generating” manner. Larger and well powered
samples are warranted to confirm (or deny) the current prelimi-
nary results, and to discover additional potential genetic variants
associated with compensatory potential in PD.
FUTURE DIRECTION IN NEUROIMAGING-GENETIC STUDIES
FOR PD’s COMPENSATORY MECHANISMS
In contrast to the candidate gene approach, implementing the
hypothesis free GWAS, will enable to identify other genes, not
restricted to the “usual suspects” of dopamine homeostasis in the
striatum but also unexpected ones, advancing the field beyond
current knowledge. These may include, for example, genes and
pathways involved in novel mechanisms of attenuating the indi-
rect pathway activity, or affecting regions and network in the
cortex and cerebellum. It should be acknowledged, however,
that the current analytic approach is in line with the “com-
mon disease-common variant” hypothesis, resuming that large
number of common genetic variants account for the genetic
contribution to the phenotype, and each SNP has a small size
effect. However, low frequency and even rare variants (with
large effect size and variable penetrance) may also play role
in genetic contribution to compensatory mechanisms in PD.
To systematically evaluate the compensatory potential of low
frequency/rare variants such as these, very large samples are
required, incorporating methods such as whole exome/genome
sequencing.
Beside valuable insight to development of PDmodifying drugs
that slow rate of disease progression, identification of genetic vari-
ants involved in endogenous compensatory mechanisms can lead
to “individualized medicine.” A priori identification of patients
carrying variants that increase the compensatory potential may
have impact on therapeutic decisions. This can also bear impli-
cations for patients’ stratification in clinical trials, evaluating
efficacy of novel drugs.
Our genomic imaging model, with appropriate adaptation,
might be applicable not only for prediction of motor severity
in PD but also to other non-motor symptoms such as demen-
tia. Also, it can be used in other neurodegenerative diseases. For
example, improvement of imaging strategies in Alzheimer dis-
ease will enable to find genes and molecular pathways involved
in disease progression, in a similar way.
As a final point, one should keep in mind that compensatory
mechanisms in PD probably represent complex and different
processes in various disease stages, not related only to genetics
but also to environmental, demographic and stochastic factors.
Careful planning of future studies, taking these important factors
into account is required.
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APPENDIX METHODS
SPECT IMAGING
All patients received potassium iodide orally to block thyroid
uptake of free radioactive iodide. A dose of 185 MBq [123I]-
FP-CIT was injected intravenously, and imaging was performed
3 h later. The SPECT study was performed using a dual-head
γ-camera (Helix; Elscint) equipped with a low-energy, high-
resolution collimator. A 20% window was centered on the 159-
keV photopeak of 123I. One hundred twenty frames of 15 s
each were acquired into a 128× 128 image matrix using a cir-
cular rotation mode. Transaxial, coronal, and sagittal slices 1
pixel thick were reconstructed using a third-order Metz fil-
ter set to 12-mm full width at half maximum. Attenuation
was corrected with a constant linear attenuation coefficient
of 0.11 cm−1.
ANALYSIS OF SPECT RESULTS
For analysis of striatal [123I]-FP-CIT binding, the two transaxial
slices representing the most intense striatal binding were summed
and subjected to qualitative analysis of tracer activity in the stri-
atal regions. For quantitative analysis of tracer uptake, regions
of interest (ROIs) were constructed manually with the help of a
brain atlas in areas corresponding to the right and left putamen,
caudate, and overall striatum. For background evaluation, ROI’s
were also drawn bilaterally in areas corresponding to the medial
occipital lobe. For each ROI, mean counts were measured, and
specific [123I]-FP-CIT uptake was calculated according to the fol-
lowing formula: specific [123I]-FP-CIT uptake = (mean activity in
ROI − mean activity in occipital cortex)/mean activity in occipi-
tal cortex. SPECT analysis was performed by an expert in Nuclear
medicine who was blinded to the patients’ disease duration.
FIGURE A1 | Boxplot of UPDRS scores at DAT scan, classified by carriership of the rs6356 “A” allele [“0” means non-carriers of “A” allele (n = 8), “1”
means carriers “A” allele (AA or AG genotype) (n = 20)].
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Table A1 | Univariate associations (t-tests) of tagging SNPSs and UPDRS scores.
Gene SNP Comparison groups (genotypes) t, df P-value
TH Rs6356 GG/AA+GA 2.94, 26 0.007
Rs10840489 CC/TT+CT (−1.95), 25 0.06
Rs10770141 GG/AA+GA 0.71, 26 0.48
COMT Rs933271 TT/CC+TC (−0.38), 26 0.7
Rs740603 GG/AA+GA (−0.95), 26 0.34
Rs16982844* NA NA NA
Rs4646312 TT/CC+TC 0.81, 26 0.42
Rs4680† AA/GG+AG 0.78, 26 0.44
GG/AA+AG (−0.27), 26 0.78
Rs4646316 CC/TT+CT 0.23, 26 0.81
Rs165774 GG/AA+GA 0.15, 26 0.87
Rs174696 TT/CC+TC (−0.03), 26 0.97
rs9332377 CC/TT+CT 0.60, 26 0.55
rs737866 TT/CC+TC (−1.32), 26 0.13
rs5993883 GG/TT+GT (−0.16), 26 0.77
MAO-A rs2235185 CC/TT+CT 0.27, 26 0.78
rs3027392 GG/AA+AG (−0.16), 26 0.87
rs3027399** GG/CC+CG 0.24, 26 0.81
rs5906957 GG/AA+AG 0.91, 26 0.37
rs909525 AA/GG+AG 0.7, 26 0.49
MAO-B rs10521432 GG/AA+AG 1, 26 0.32
rs1799836 AA/GG+AG 0.82, 25 0.42
rs2311013* NA NA NA
rs3027448 TT/CC+CT (−1), 26 0.327
rs4824562* NA NA NA
rs5905449 GG/AA+AG 1.07, 26 0.29
rs5905512 AA/GG+AG 0.89, 25 0.38
*MAF < 0.05.
**MAF < 0.1.
†The two alleles had equal frequencies (0.5).
Bold value indicates p < 0.05.
Table A2 | Summary of the linear regression model predicting UPDRS score by model; Block 2 was entered in a stepwise manner.
Block Variable B SE β t p-value Cumulative R2
2A: LINEAR REGRESSIONMODEL PREDICTING UPDRS BY TRACER UPTAKE IN THE CONTRALATERAL CAUDATE
Constant 16.69 3.34 4.99 <0.001
1 Duration of PD (months) 1.143 0.502 0.355 2.274 0.032
Absorption level in contralateral caudate −2.1 0.92 −0.33 −2.27 0.03 0.37 (p = 0.003)
2 rs6356 (carriership of A allele) −4.48 1.75 −0.39 −2.56 0.01 0.5 (p = 0.001)
2B: LINEAR REGRESSION MODEL PREDICTING UPDRS BY MEAN TRACER UPTAKE IN BOTH SIDES OF PUTAMEN
Constant 14.605 3.159 4.623 0.000
1 Duration of PD (months) 1.096 0.533 0.340 2.054 0.051
Absorption level in putamen (ipsi-and contralateral) −2.087 1.235 −0.263 −1.690 0.104 0.32 (p = 0.008)
2 rs6356 (carriership of A allele) −4.571 1.842 −0.406 −2.481 0.020 0.46 (p = 0.002)
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